Marshall Wace LLP Purchases 137,593 Shares of Liquidia Co. (NASDAQ:LQDA)

Marshall Wace LLP increased its holdings in shares of Liquidia Co. (NASDAQ:LQDA - Free Report) by 92.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 286,289 shares of the company's stock after purchasing an additional 137,593 shares during the period. Marshall Wace LLP owned approximately 0.34% of Liquidia worth $3,367,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. LM Advisors LLC acquired a new stake in shares of Liquidia during the 4th quarter worth approximately $25,948,000. Invesco Ltd. grew its holdings in Liquidia by 2,675.0% in the fourth quarter. Invesco Ltd. now owns 700,171 shares of the company's stock worth $8,234,000 after purchasing an additional 674,940 shares during the period. Renaissance Technologies LLC bought a new stake in Liquidia in the fourth quarter valued at $2,681,000. JPMorgan Chase & Co. boosted its position in shares of Liquidia by 855.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 235,393 shares of the company's stock worth $2,354,000 after purchasing an additional 210,753 shares in the last quarter. Finally, Rangeley Capital LLC acquired a new stake in shares of Liquidia in the 4th quarter valued at about $2,246,000. 64.54% of the stock is currently owned by institutional investors.

Insider Activity at Liquidia

In other news, CEO Roger Jeffs sold 14,130 shares of the stock in a transaction on Monday, April 14th. The shares were sold at an average price of $13.57, for a total value of $191,744.10. Following the transaction, the chief executive officer now owns 1,006,420 shares of the company's stock, valued at $13,657,119.40. This represents a 1.38 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, General Counsel Russell Schundler sold 5,964 shares of Liquidia stock in a transaction dated Monday, April 14th. The stock was sold at an average price of $13.57, for a total value of $80,931.48. Following the sale, the general counsel now directly owns 570,301 shares of the company's stock, valued at approximately $7,738,984.57. This trade represents a 1.03 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 33,138 shares of company stock valued at $450,233. Corporate insiders own 30.10% of the company's stock.

Liquidia Stock Up 1.1 %

Liquidia stock traded up $0.16 during midday trading on Thursday, hitting $14.13. 164,960 shares of the stock were exchanged, compared to its average volume of 971,785. The stock has a market capitalization of $1.20 billion, a price-to-earnings ratio of -8.69 and a beta of 0.23. Liquidia Co. has a 52-week low of $8.26 and a 52-week high of $16.81. The business's 50-day moving average price is $14.25 and its 200-day moving average price is $12.95.

Liquidia (NASDAQ:LQDA - Get Free Report) last posted its quarterly earnings data on Wednesday, March 19th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.08). Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%. The firm had revenue of $2.92 million during the quarter, compared to analysts' expectations of $4.60 million. On average, sell-side analysts predict that Liquidia Co. will post -1.51 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on LQDA shares. HC Wainwright restated a "buy" rating and set a $29.00 price objective on shares of Liquidia in a report on Thursday, March 20th. Scotiabank restated an "outperform" rating on shares of Liquidia in a report on Thursday, March 20th. Finally, Needham & Company LLC reissued a "buy" rating and set a $25.00 target price on shares of Liquidia in a research report on Thursday, April 10th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, Liquidia presently has a consensus rating of "Buy" and a consensus target price of $26.63.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).